menu
    • menu
    [{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"TTP399","moa":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"vTv Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"vTv Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"TTP399","moa":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"vTv Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"vTv Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"TTP399","moa":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"vTv Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"vTv Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"TTP399","moa":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"vTv Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"vTv Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"TTP399","moa":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"vTv Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"vTv Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"TTP399","moa":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"vTv Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"vTv Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"TTP399","moa":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"vTv Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"vTv Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"G42 Investments","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"TTP399","moa":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"vTv Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0.059999999999999998,"dosageForm":"Tablet","sponsorNew":"vTv Therapeutics \/ G42 Investments","highestDevelopmentStatusID":"8","companyTruncated":"vTv Therapeutics \/ G42 Investments"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"TTP399","moa":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"vTv Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"vTv Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"CinPax","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"Cadisegliatin","moa":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"vTv Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"vTv Therapeutics \/ CinPax","highestDevelopmentStatusID":"8","companyTruncated":"vTv Therapeutics \/ CinPax"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Reneo Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"Cadisegliatin","moa":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"vTv Therapeutics \/ Reneo Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"vTv Therapeutics \/ Reneo Pharmaceuticals"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Samsara BioCapital, LLC","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2024","type":"Private Placement","leadProduct":"Cadisegliatin","moa":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"vTv Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0.050000000000000003,"dosageForm":"Tablet","sponsorNew":"vTv Therapeutics \/ Samsara BioCapital, LLC","highestDevelopmentStatusID":"8","companyTruncated":"vTv Therapeutics \/ Samsara BioCapital, LLC"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Cadisegliatin","moa":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"vTv Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"vTv Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Cadisegliatin","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"vTv Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"vTv Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Cadisegliatin","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"vTv Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"vTv Therapeutics \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Cadisegliatin

    Menu

    Cadisegliatin

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            vTv Therapeutics

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            vTv Therapeutics

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cadisegliatin

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            vTv Therapeutics Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold

                            Details : TTP399 (cadisegliatin) is an investigational liver-selective glucokinase activator that has been studied in healthy volunteers and in patients with type 1 and type 2 diabetes.

                            Brand Name : TTP399

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 26, 2024

                            Lead Product(s) : Cadisegliatin

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            vTv Therapeutics

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            vTv Therapeutics

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cadisegliatin

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            vTv Announces Screening of First Patient in CATT1 Trial for Type 1 Diabetes

                            Details : TTP399 (cadisegliatin) is a novel, oral small molecule, liver-selective glucokinase activator with first-in-class potential as an adjunct treatment for type 1 diabetes.

                            Brand Name : TTP399

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 24, 2024

                            Lead Product(s) : Cadisegliatin

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            vTv Therapeutics

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            vTv Therapeutics

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cadisegliatin

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            vTv Submits FDA Application for First Phase 3 Study of Cadisegliatin in Type 1 Diabetes

                            Details : TTP399 (cadisegliatin) is an investigational liver-selective glucokinase activator that has been studied in healthy volunteers and in patients with type 1 and type 2 diabetes.

                            Brand Name : TTP399

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 04, 2024

                            Lead Product(s) : Cadisegliatin

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            vTv Therapeutics

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            vTv Therapeutics

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cadisegliatin

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Samsara BioCapital, LLC

                            Deal Size : $51.0 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            vTv Therapeutics Announces $51 Million Private Placement

                            Details : vTv will utilize the net proceeds to finance the initial Phase 3 trial of its primary product candidate, TTP399 (cadisegliatin), a glucokinase activator intended for treating type 1 diabetes.

                            Brand Name : TTP399

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            February 28, 2024

                            Lead Product(s) : Cadisegliatin

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Samsara BioCapital, LLC

                            Deal Size : $51.0 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            vTv Therapeutics

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            vTv Therapeutics

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cadisegliatin

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase II

                            Sponsor : Reneo Pharmaceuticals

                            Deal Size : $4.4 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            vTv Therapeutics Announces Sale of Shares in Reneo Pharmaceuticals for Proceeds of $4.4 Million

                            Details : The proceeds will provide vTv with important financial support for preparing the launch of the TTP399 (cadisegliatin), a potential adjunctive therapy to insulin, phase 3 program in the treatment of type 1 diabetes.

                            Brand Name : TTP399

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            November 01, 2023

                            Lead Product(s) : Cadisegliatin

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase II

                            Sponsor : Reneo Pharmaceuticals

                            Deal Size : $4.4 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            vTv Therapeutics

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            vTv Therapeutics

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cadisegliatin

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase I/ Phase II

                            Sponsor : CinPax

                            Deal Size : $10.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            vTv Therapeutics Announces Investment by CinRx Pharma

                            Details : In addition to the investment, the agreements set forth the terms under which vTv will leverage the CinRx team’s industry experience to collaborate on the oversight of the clinical trials for pharmaceutical products that contain TTP399.

                            Brand Name : TTP399

                            Molecule Type : Small molecule

                            Upfront Cash : $6.0 million

                            July 25, 2022

                            Lead Product(s) : Cadisegliatin

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : CinPax

                            Deal Size : $10.0 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            vTv Therapeutics

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            vTv Therapeutics

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cadisegliatin

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            vTv Therapeutics Announces Publication in Diabetes Obesity and Metabolism of Complete Results for the Mechanis...

                            Details : Results confirmed TTP399 improves glycemia without increasing hypoglycemia and suggest a protective effect of TTP399 against DKA in individuals with T1D.

                            Brand Name : TTP399

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 04, 2022

                            Lead Product(s) : Cadisegliatin

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            vTv Therapeutics

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            vTv Therapeutics

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cadisegliatin

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase II

                            Sponsor : G42 Investments

                            Deal Size : $55.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            vTv Therapeutics Announces Investment by And Entry Into Collaboration and License Agreement with Affiliates of...

                            Details : The agreements set forth the terms under which vTv and an affiliate of G42 plan to collaborate on clinical trials for pharmaceutical products that contain TTP399, including G42’s affiliate funding a portion of the Phase 3 clinical trials for TTP399.

                            Brand Name : TTP399

                            Molecule Type : Small molecule

                            Upfront Cash : $12.5 million

                            June 01, 2022

                            Lead Product(s) : Cadisegliatin

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase II

                            Sponsor : G42 Investments

                            Deal Size : $55.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            vTv Therapeutics

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            vTv Therapeutics

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cadisegliatin

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            vTv Therapeutics Shares Updated Corporate Presentation

                            Details : TTP399, a novel oral liver-selective glucokinase activator, as a transformative treatment in the reduction of hypoglycemic episodes for the global diabetes population, has been tested in almost 600 patients to date with no evidence of diabetic ketoacidos...

                            Brand Name : TTP399

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 13, 2022

                            Lead Product(s) : Cadisegliatin

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            vTv Therapeutics

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            vTv Therapeutics

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cadisegliatin

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            vTv Therapeutics Receives FDA Breakthrough Therapy Designation for TTP399 for the Treatment of Type 1 Diabetes

                            Details : The Breakthrough Therapy designation for TTP399 in type 1 diabetes was supported by the recent positive results from the phase 2 SimpliciT-1 study assessing the safety and efficacy of TTP399 as an adjunct to insulin therapy in adults with type 1 diabetes...

                            Brand Name : TTP399

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 13, 2021

                            Lead Product(s) : Cadisegliatin

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth